filmov
tv
The future of allo-HSCT - C. Peters (AT)
Показать описание
SIOPE
Рекомендации по теме
0:47:29
The future of allo-HSCT - C. Peters (AT)
0:39:01
Indications for allogeneic stem cell transplantation in AML
0:03:43
The role of allo-HSCT in treating relapsed patients with multiple myeloma
0:08:29
Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
0:04:44
When should we consider allo-HSCT in a patient with ALL? And when not?
0:02:30
Impact of gut mycobiota on outcomes after allo-HSCT
0:07:50
How might itacitinib prophylaxis impact haplo-HSCT outcomes in the future?
0:01:23
Current status of alloHSCT in BP-MPNs
0:03:23
The role of allo-transplant for patients with ALL
0:00:33
Unmet needs in MDS: treating relapse after alloHSCT & TP53-mutated disease
0:13:34
Debate: Is allotransplant relevant today in myeloma? - Yes
0:07:12
The role of autologous transplant in the future treatment of MM
0:02:12
Mutation profile in CMML undergoing allo-HSCT
0:02:26
Allo-HSCT and novel drugs for refractory AML
0:02:00
The future of CAR-T therapy and the role of transplantation within this field
0:03:00
The oral microbiome and metabolome of alloHSCT recipients who develop oral mucositis
0:01:22
REACT: ELISPOT assay predicts CMV reactivation in allo-HSCT patients
0:04:05
CMV infection monitoring after alloHSCT
0:01:21
Novel targets and the future role of combinations for myeloma
0:00:52
The future of CAR T-cell therapy for AML
1:34:00
Future of allogeneic transplant in AML
0:07:10
Practical Advice on the Future Management of MCL
0:02:10
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or PFS compared to Tac/MTX in GVHD
0:03:23
Allogeneic Stem Cell Transplant: What You Need to Know
welcome to shbcf.ru
0:47:29
0:39:01
0:03:43
0:08:29
0:04:44
0:02:30
0:07:50
0:01:23
0:03:23
0:00:33
0:13:34
0:07:12
0:02:12
0:02:26
0:02:00
0:03:00
0:01:22
0:04:05
0:01:21
0:00:52
1:34:00
0:07:10
0:02:10
0:03:23